Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation (clinicaltrials.gov) - Oct 14, 2026 - P1/2 | N=55 | Active, not recruiting | Sponsor: Institut de Recherches Internationales Servier | Recruiting ➔ Active, not recruiting | Trial primary completion date: Jul 2026 ➔ Sep 2027
Enrollment closed • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • IDH1
|